Stay updated with breaking news from Nasdaq Bpmc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective hoisted by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upped their price objective on […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total value of $1,050,000.00. Following the transaction, the chief financial officer now owns 47,286 shares of […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $125.00 to $135.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential […]
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective increased by JMP Securities from $114.00 to $125.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. BPMC has been the subject of a number of other research reports. Barclays lifted their target […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […]